Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 2nd, 2022

New therapies for cardiovascular disease reach clinical trial stage


Headshots of Drs. Daughtery, Schmit
Ann Marie Schmidt, MD, FAHA (left), Alan Daugherty, PhD, DSc, FAHA

Genomic-based therapies for cardiovascular disease are emerging fast in research and could soon be used regularly in hospitals and practices around the world — changing future treatment, said Ann Marie Schmidt, MD, FAHA.

“The concept of therapeutic, genomic-based therapies for cardiovascular diseases has now reached clinical trials,” said Schmidt, professor of biochemistry, molecular pharmacology and pathology at NYU Langone Health in New York City. 

“This area of research and medicine offers landmark, game-changing opportunities for diseases in which genomic profiling in humans (and in animals) has shed light on key mechanisms of disease.” 

Several areas of the research will be highlighted in Saturday’s session, “Identifying and Practicing Emerging Genomic-Based Therapies on Cardiovascular Disease.” Dr. Schmidt said the session — co-moderated by Alan Daugherty, PhD, DSc, FAHA, associate vice president for research and physiology chair at the University of Kentucky College of Medicine in Lexington — will focus on several key areas of genomic therapies, including: 

  • PCSK9 gene for cholesterol metabolism
  • TTR gene for amyloidosis and heart disease
  • Angiotensinogen for blood pressure regulation
  • Hemophilia for bleeding disorders
  • ApoC3, Angptl3 for dyslipidemia disorders

The move from animal testing to human subjects represents a significant leap forward for these therapies, Dr. Schmidt said. 

“The work in many cases has moved from understanding basic mechanisms in animal model systems to application to human subjects, thereby underscoring the immense value of basic to translational/clinical to population level research,” she said. 

Genomic profiling, Dr. Daugherty said, allows researchers to identify the genes in a person or specific cell type and how those genes interact with each other and the environment. This aids in the mission to personalize medicine with respect to a physician’s ability to diagnose, treat and prevent diseases. 

“Genomic profiling holds great promise to help us understand why certain people are vulnerable to certain diseases while others are not,” Dr. Daugherty said. “And also to begin to predict which patients may or may not respond to specific therapies. By better understanding how the uniqueness of each person renders them more or less vulnerable to disease and more or less likely to respond to specific therapies, these methods may personalize therapies for cardiovascular diseases.” 

Several areas of study will be important in this field in the future, where genomic profiling will have broad reach, according to Dr. Schmidt. These include lipid disorders (including cholesterol) and the impacts for atherosclerosis; renin-angiotensin system targets that could impact treatment of hypertension; and blood disorders and the treatment of hemophilia. 

As these areas of research move further into human trials, Dr. Schmidt said the impact on patient health care could be tremendous. 

“The realization of some of these new targets for human clinical trials and testing are critical examples of the success of biomedical research and the likelihood for important impact on the heath and lifespans of individual people,” she said.

Interesting Stories
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
More Content
audience
AHA22
Early ablation bests medication in treatment naïve AFib patients
Nov 9th, 2022
audience shot
AHA22
First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
Nov 9th, 2022
Manesh Patel
AHA22
#AHA 22 Closing Session: That’s a wrap
Nov 9th, 2022
Getty Images 1388100332
AHA22
Congratulations to the winners of the Wellness Challenge and Scavenger Hunt
Nov 8th, 2022
puppy snugglers
AHA22
Special Recognition to the Hinsdale Humane Society
Nov 8th, 2022
audience shot
AHA22
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
Nov 8th, 2022
LBS 05 panelists
AHA22
Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression
Nov 8th, 2022
Medtech
AHA22
Medtech is getting smarter — and so is patient care
Nov 7th, 2022
med tech checking fluids in a hospital
AHA22
New digital hub offers professional education to complement lifelong learning
Nov 7th, 2022
AHA speaker dais
AHA22
Uncovering novel approaches in heart failure science
Nov 7th, 2022
Aha22 Sm 2334
AHA22
Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock
Nov 7th, 2022
Aha Ss22 Days123 Pg1
AHA22
Read all about it
Nov 7th, 2022